Shanghai Haoyuan Chemexpress Co., Ltd. Share Price

Equities

688131

CNE1000051J4

Pharmaceuticals

End-of-day quote Shanghai S.E. 03:30:00 30/04/2024 am IST 5-day change 1st Jan Change
33.13 CNY -0.69% Intraday chart for Shanghai Haoyuan Chemexpress Co., Ltd. +12.42% -36.36%

Financials

Sales 2024 * 2.45B 338M 28.24B Sales 2025 * 3.16B 436M 36.39B Capitalization 4.98B 688M 57.44B
Net income 2024 * 157M 21.69M 1.81B Net income 2025 * 226M 31.22M 2.61B EV / Sales 2024 * 2.03 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 1.58 x
P/E ratio 2024 *
27.9 x
P/E ratio 2025 *
19.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 40.48%
More Fundamentals * Assessed data
Dynamic Chart
Haoyuan Chemexpress to Issue 822 Million Yuan Worth of Convertible Bonds MT
Haoyuan Chemexpress to Raise Subsidiary's Capital by 200 Million Yuan MT
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shanghai Haoyuan Chemexpress Co., Ltd.(XSSC:688131) added to S&P Global BMI Index CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shanghai Haoyuan Chemexpress Shareholders Plan to Unload Company's Stakes CI
Shanghai Haoyuan Chemexpress Co., Ltd.(SHSE:688131) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Haoyuan Chemexpress to Build Drug Center for 500 Million Yuan MT
Haoyuan Chemexpress Logs 1.4% Rise in 2022 Profit MT
Shanghai Haoyuan Chemexpress Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Haoyuan Chemexpress Raising 50 Million Yuan From Controlling Shareholder to Buy Local Drugmaker MT
Shanghai Haoyuan Chemexpress Co., Ltd. announced that it has received CNY 49.999962 million in funding from Shanghai Anxu Information Technology Co., Ltd., Shanghai Yuanmeng Enterprise Management Consulting Partnership (Limited Partnership), Ningbo Jiusheng Innovation Pharmaceutical Technology Co., Ltd, Shanghai Yuanli Enterprise Management Partnership CI
Shanghai Haoyuan Chemexpress Co., Ltd. completed the acquisition of 2Y-Chem, Ltd. from Ningbo Jiusheng Innovative Pharmaceutical Technology Co., Ltd., Qidong Yuanli Enterprise Management Consulting Partnership (Limited Partnership), Shanghai Yuanmeng Enterprise Management Consulting Partnership (Limited Partnership) and WANG YUAN. CI
More news
1 day-0.69%
1 week+12.42%
Current month-4.19%
1 month-4.19%
3 months-11.65%
6 months-47.25%
Current year-36.36%
More quotes
1 week
29.63
Extreme 29.63
33.58
1 month
28.43
Extreme 28.43
36.01
Current year
26.00
Extreme 26
51.99
1 year
26.00
Extreme 26
83.33
3 years
26.00
Extreme 26
216.84
5 years
26.00
Extreme 26
216.84
10 years
26.00
Extreme 26
216.84
More quotes
Managers TitleAgeSince
Founder 51 30/06/30
Chief Executive Officer 45 30/06/30
Chairman 56 01/20/01
Members of the board TitleAgeSince
Director/Board Member 43 20/19/20
Director/Board Member 38 23/15/23
Chief Executive Officer 45 30/06/30
More insiders
Date Price Change Volume
30/24/30 33.13 -0.69% 1,385,106
29/24/29 33.36 +3.09% 1,787,940
26/24/26 32.36 +3.45% 2,098,442
25/24/25 31.28 +4.02% 2,053,873
24/24/24 30.07 -0.30% 1,160,053

End-of-day quote Shanghai S.E., April 30, 2024

More quotes
Shanghai Haoyuan Chemexpress Co Ltd is a China-based company mainly engaged in the research and development, production and sales of small molecule drugs. The Company's main products include molecular building blocks and tool compounds. The Company's products also include active pharmaceutical ingredients (APIs) and intermediates. The Company also provides related services such as contract research organization (CRO) service. The Company's molecular building blocks and tool compounds are applied in all stages of the drug discovery process. The Company distributes its products in domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
33.13
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688131 Stock